Atrium Medical Corporation
$13.1K 18 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Ipsen Biopharm Limited
Ipsen Biopharm Limited reported $13,054.05 across General Payments, Research, and Ownership to 5 physicians and teaching hospitals across 5 transactions.
- $13.1K Below-median payer
- All-tracks total
- 5 Below-median volume
- Transactions
- 5 Below-median reach
- Recipients
- #1601
- of 1,925 companies
Ipsen Biopharm Limited reported $13,054.05 across all CMS Open Payments tracks (General + Research + Ownership) to 5 physicians and teaching hospitals in Program Year 2024 - ranking #1601 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $13,054.05, averaging $2.6K per recipient.
Ipsen Biopharm Limited's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ipsen-biopharm-limited Ipsen Biopharm Limited
$13.1K · #1601/1,925 · 0.0% industry · PY2024
- TOT $13.1K
- RANK #1601
- SHARE 0.0%
- TXN 5
- RCP 5
- CAT 3
- GEN $13.1K
- TOP1 67.4%
- PY 2024
Volume peers
Nearest volume peer: Atrium Medical Corporation ($13.1K)
Ipsen Biopharm Limited sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Ipsen Biopharm Limited
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Ipsen Biopharm Limited that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Consulting Fee" leads the 3-category general-payment breakdown below at $13.0K (99.3% of General Payments, 3 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Consulting Fee" leads Ipsen Biopharm Limited's 3-category general-payment breakdown at $13.0K, 99.3% of the reported total.
How Ipsen Biopharm Limited divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $13.0K | 3 | 99.3% |
| Travel and Lodging | $83.55 | 1 | 0.6% |
| Food and Beverage | $10.50 | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $13,054.05 (100.0%) of $13,054.05 in this company's General Payments records across 2 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ipsen Biopharm Limited
The five named recipients with the highest reported General Payments from this company
- 1
Alberto Esquenazi
$8,794.05 across 4 reported transactions
- 2
Richard D Zorowitz
$4,260.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ipsen Biopharm Limited ranks #1601 of 1,925 by total payments (bottom 17% by spend) but is notably more concentrated than that alone would suggest -- #293 of 1,838 by HHI (top 16% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Atos Medical Inc : $110.5K total payments, HHI 5624
- Zerigo Health, Inc. : $7.5K total payments, HHI 5622
- Medivation Services LLC : $192.46 total payments, HHI 5620
- Inpeco North America, Inc : $7.5K total payments, HHI 5612
- FFF Enterprises, Inc. : $3.6K total payments, HHI 5610
- Retropsoas Technologies, LLC : $14.6K total payments, HHI 5606
- Ipsen Biopharm Limited (this company) : $13.1K total payments, HHI 5603
- BlueRock Therapeutics LP : $405.9K total payments, HHI 5593
- Nidek Co., Ltd. : $29.8K total payments, HHI 5592
- DiaSorin Inc. : $371.5K total payments, HHI 5574
- Bavarian Nordic A/S : $68.0K total payments, HHI 5563
- Mindera Corp : $7.5K total payments, HHI 5556
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ipsen Biopharm Limited's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ipsen Biopharm Limited.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ipsen Biopharm Limited.
Showing 6 of 1,924 companies with CMS-reported payment data.
Medynus Inc
$13.0K 4 recipients
Compare payment profiles
Notal Vision, Inc.
$13.1K 541 recipients
Compare payment profiles
Carmat
$13.2K 0 recipients
Compare payment profiles
DC Dental, LLC
$12.9K 49 recipients
Compare payment profiles
Uc-Care (usa), Inc
$12.9K 3 recipients
Compare payment profiles
Put this to use
Ipsen Biopharm Limited ranks #1601 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Ipsen Biopharm Limited. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.